Massachusetts General Hospital at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Massachusetts General Hospital takes part in 6 sessions at ESMO 2026 in Madrid. Its sessions focus on hormone receptor-positive, HER2-negative breast cancer, including CDK4/6 inhibitors for patients with lymph node involvement, and biomarkers for first-line metastatic non-small cell lung cancer. It also reports early results for an antibody against galectin-9 in relapsed myelodysplastic syndrome and acute myeloid leukaemia.
| Organization | ESMO 2026 Attendance |
|---|---|
Massachusetts General Hospital Boston, MA | |
Teaching hospital of Harvard Medical School in Boston, Massachusetts, with a cancer centre. | Satellite Fri Oct 23 18:20–18:40 Satellite Fri Oct 23 18:40–19:00 Advances in 1L therapy for metastatic NSCLC: Current and emerging biomarkers and treatment strategies Lung & thoracic cancersBiomarkers & precision oncology Satellite Fri Oct 23 19:40–19:45 Close Breast cancer Abstract Sat Oct 24 09:35–09:45 Abstract Sun Oct 25 08:30–08:40 LBA42 - HexAgon-HN: a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1– high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)—phase 2 primary analysis Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 09:00–09:12 Invited Discussant LBA69, 2615O and one LBA TBC Lung & thoracic cancers Satellite Mon Oct 26 13:10–13:30 |
Instantly find 20 buyers from Massachusetts General Hospital
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction